<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753477</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1351004</org_study_id>
    <nct_id>NCT03753477</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Efficacy and Safety of DWJ1351</brief_title>
  <official_title>An Open-label, Randomized, 2X2 Crossover Study to Compare the Pharmacokinetics and Safety Between DWJ1351 and Co-administration of Amlodipine/Olmesartan and Rosuvastatin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetic characteristics of
      combination of amlodipine, olmesartan and rosuvastatin and DWJ1351 in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetic characteristics of
      combination of amlodipine, olmesartan and rosuvastatin and DWJ1351 in healthy male
      volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>t1/2β</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vdss/F</measure>
    <time_frame>[ Time Frame: 0 - 72 hours ]</time_frame>
    <description>Vdss/F</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevikar and Crestor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)</intervention_name>
    <description>DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)</description>
    <arm_group_label>Test Drug</arm_group_label>
    <other_name>DWJ1351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevikar and Crestor</intervention_name>
    <description>Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)</description>
    <arm_group_label>Reference Drug</arm_group_label>
    <other_name>Amlodipine/Olmesartan and Rosuvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who provided written informed consent to participate in this study

          -  Healthy adult male subjects aged 19 to 50 years

          -  Subjects whose body weight ≥ 55 kg and Body Mass Index(BMI) ≥ 18.0 kg/m2 and ≤ 27.0
             kg/m2

          -  Subject who was judged to be healthy and suitable for the participation by the
             investigator based on screening test results

        Exclusion Criteria:

          -  Subject who had a severe allergy or allergic reactions to the amlodipine, olmesartan,
             rosuvastatin or related drugs

          -  Subjects who had a serious clinical illness that can impact fate of drugs absorption

          -  Subject who shows vital signs with the number of systolic blood pressure of &gt;140 mmHg
             or &lt;100 mmHg, and the number of diastolic blood pressure of &gt;90mmHg or &lt;65mmHg

          -  Subject who have experienced drug abuse

          -  Subject who donates his blood (whole blood donation within last 2 months or plasma
             donation within last 1 month)

          -  Subject who has taken other clinical or licensed medication from another clinical
             trial within an 3-month period prior to the first administration of the study
             medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JG Shin, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan Paik Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Amlodipine Besylate, Olmesartan Medoxomil Drug Combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

